Liquidia Loses About Half Its Value After Court Finds Yutrepia Infringes Two United Therapeutics Patent Claims
SentiSense · Published · Updated
A federal court in Delaware ruled on September 30, 2026 that Liquidia's inhaled treprostinil Yutrepia infringes claims 1 and 14 of United Therapeutics...
Sign in to read the full story. Free accounts include 20 full reads a month.
Powered by SentiSense - Intelligent Market Analysis